The intelligent search engine for biomedical specialists

"GoPubMed is a sort of an intelligent Google for biomedical specialists," explains Dr Michael Alvers, CEO and Co-founder of Transinsight. "The search engine saves time and so accelerates research significantly."

Founded in November 2005, Transinsight is a software company focused on the life sciences that provides products and solutions for intelligent search technologies. Their main product, GoPubMed, was partly developed during the IST project, Biogrid, by Professor Michael Schroeder and his research team from the Biotechnology Centre at the Technical University of Dresden.

"Biomedical researchers have to be familiar with a huge number of publications," notes Schroeder, Transinsight's Chief Scientific Officer and Co-founder. "The PubMed database currently contains 15 million biomedical publications that have to be assessed by research groups."

"Researchers in the biotech and pharmaceutical industries spend an average of 12.4 hours a week searching for relevant information," adds Alvers.

GoPubMed can search literature repositories, websites, intranets and desktops. It indexes results and thus allows users to explore a large body of results in a structured manner.

In contrast to classical search engines, GoPubMed can answer questions using its background knowledge in molecular biology, medicine, drug development and food science. To illustrate this point, a search for 'aspirin inhibits' on a classical search engine returns a large number of unstructured results that do not answer the user's original question. On the other hand, a search with GoPubMed reveals that the most frequently mentioned pathway for 'aspirin inhibits' is the cyclooxygenase pathway.

Schroeder stresses, "GoPubMed] is intelligent and presents the search results in a way that is specifically linked to the interests of a particular research group."

Thanks to its groundbreaking and competitive product, the young company has already won its first corporate customer – Unilever in the UK. Explaining why Unilever decided to purchase the software, Dr Cecilia Eyre remarks "GoPubMed helps us to quickly screen the vast literature for hidden gems and to discover trends in science."

With exciting commercial prospects, the start-up company has also been quick to attract investment. This past January, it was announced that Transinsight had received €500,000 of seed funding from Germany's recently established High-Tech-Gründerfonds and a further undisclosed sum from a private investor in Hamburg.

Indeed, such are the high expectations for Transinsight, that the firm was very recently crowned as one of only three 'Lighthouse projects of the High-Tech-Gründerfonds' by Michael Glos, German Federal Minister for Economic Affairs and Technology.

Contact:
Dr Michael R. Alvers
CEO
Transinsight GmbH
Tatzberg 47-51
D-01307 Dresden
Germany
Tel: +49-351-46340059
Fax: +49-351-46340061
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Source: IST Results Portal

Most Popular Now

AI Tool Offers Deep Insight into the Imm…

Researchers explore the human immune system by looking at the active components, namely the various genes and cells involved. But there is a broad range of these, and observations necessarily...

Do Fitness Apps do More Harm than Good?

A study published in the British Journal of Health Psychology reveals the negative behavioral and psychological consequences of commercial fitness apps reported by users on social media. These impacts may...

AI Tool Beats Humans at Detecting Parasi…

Scientists at ARUP Laboratories have developed an artificial intelligence (AI) tool that detects intestinal parasites in stool samples more quickly and accurately than traditional methods, potentially transforming how labs diagnose...

Making Cancer Vaccines More Personal

In a new study, University of Arizona researchers created a model for cutaneous squamous cell carcinoma, a type of skin cancer, and identified two mutated tumor proteins, or neoantigens, that...

AI, Health, and Health Care Today and To…

Artificial intelligence (AI) carries promise and uncertainty for clinicians, patients, and health systems. This JAMA Summit Report presents expert perspectives on the opportunities, risks, and challenges of AI in health...

AI can Better Predict Future Risk for He…

A landmark study led by University' experts has shown that artificial intelligence can better predict how doctors should treat patients following a heart attack. The study, conducted by an international...

A New AI Model Improves the Prediction o…

Breast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year, and continues to be one of the...

AI System Finds Crucial Clues for Diagno…

Doctors often must make critical decisions in minutes, relying on incomplete information. While electronic health records contain vast amounts of patient data, much of it remains difficult to interpret quickly...

Improved Cough-Detection Tech can Help w…

Researchers have improved the ability of wearable health devices to accurately detect when a patient is coughing, making it easier to monitor chronic health conditions and predict health risks such...

Multimodal AI Poised to Revolutionize Ca…

Although artificial intelligence (AI) has already shown promise in cardiovascular medicine, most existing tools analyze only one type of data - such as electrocardiograms or cardiac images - limiting their...

New AI Tool Makes Medical Imaging Proces…

When doctors analyze a medical scan of an organ or area in the body, each part of the image has to be assigned an anatomical label. If the brain is...